Friday, April 19, 2024
4/19/2024
Project summary Systemic lupus erythematosus (SLE) is a complex autoimmune disease predominantly affecting women. Lupus nephritis (LN), is a leading cause of high mortality. Timely treatment of LN flares with anti-inflammatory and immunosuppressant drugs is critical, but flares are not currently diagnosed in a point-of-care or home setting; the gold standard for LN flare diagnosis is renal biopsy. At-home or Point-of-care (POC) detection of LN flares would improve treatment responsiveness access and facilitate SLE clinical research. We propose 3 specific aims: AIM 1: To develop multiplex quantitative Biomarker Mini-array (BMA) for urinary SLE flare markers. AIM 2: To develop a reliable, convenient Biomarker Mini-array for LN flare identification by smartphone based analysis and reporting system (SBARS). AIM 3: To evaluate the clinical performance of the BMA-SBARS tests in disease settings, using urine samples from cross- sectional and longitudinal cohorts of LN patients. The primary innovation of the proposed work lies in its development of a prototype practical POC/self-testing urine test for LN flares. The technology itself will have broad impact in self-management of chronic diseases at home, especially for aged patients.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
